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Hamartomatous Polyposis Syndromes (HPS) are genetic syndromes, which include Peutz-Jeghers syndrome, Juvenile
polyposis syndrome, PTEN hamartoma tumour syndrome (Cowden Syndrom, Bannayan-Riley-Ruvalcaba and Proteus
Syndrome) as well as hereditary mixed polyposis syndrome. Other syndromes such as Gorlin Syndrome and
multiple endocrine neoplasia syndrome 2B are sometimes referred to as HPS. HPS is characterized by the
development of hamartomatous polyps in the gastrointestinal tract as well as several extra-intestinal findings such
as dermatological and dysmorphic features or extra-intestinal cancer. The syndromes are rare and inherited in an
autosomal dominant manner.
The diagnosis of HPS has traditionally been based on clinical criteria, but can sometimes be difficult as the severity
of symptoms range considerably from only a few symptoms to very severe cases - even within the same family.
De novo cases are also frequent. However, because of the discovery of several associated germline-mutations as
well as the rapid development in genetics it is now possible to use genetic testing more often in the diagnostic
process. Management of the syndromes is different for each syndrome as extra-intestinal symptoms and types of
cancers differs.
Clinical awareness and early diagnosis of HPS is important, as affected patients and at-risk family members should
be offered genetic counselling and surveillance. Surveillance in children with HPS might prevent or detect intestinal
or extra-intestinal complications, whereas in adulthood surveillance is recommended due to an increased risk of
cancer e.g. intestinal cancer or breast cancer.
Keywords: Hamartomatous polyposis syndromes, PTEN hamartoma tumor syndrome, Peutz-Jeghers syndrome,
Juvenile polyposis syndrome, neurofibromatosis type 1, Gorlin Syndrome, Juvenile polyp, PolyposisIntroduction
Hamartomatous Polyposis Syndromes (HPS) are rare gen-
etic syndromes characterized by the development of hamar-
tomatous polyps in the gastrointestinal tract (GI-tract).
Despite variable phenotypic expression of the syndromes
affected patients have an increased risk of cancer and sur-
veillance is relevant from an early age. The aim of this
article is to give an updated review of clinical features, gen-
etics, treatment and surveillance of HPS.
Methods
This review is based on a literature search using PubMed
and Medline including original articles, reviews, cases and
clinical guidelines. The search terms were “hamartomatous* Correspondence: anne.marie.jelsig@rsyd.dk
1Department of Clinical Genetics, Odense University Hospital and Institute of
Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000
Odense C, Denmark
Full list of author information is available at the end of the article
© 2014 Jelsig et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.polyposis syndromes”, “Peutz-Jeghers syndrome”, “juvenile
polyposis syndrome”, “Peutz-Jeghers polyp”, “juvenile polyp”,
“PTEN hamartoma tumour syndrome” (Cowden syndrome,
Bananyan-Riley-Ruvalcaba), “hereditary mixed polyposis
syndrome”, “Neurofibromatosis type 1”, “Gorlin Syndrome”
and “multiple endocrine neoplasia syndrome 2B”. Inclusion-
and exclusion criteria: Case reports, retrospective cohort
studies and papers discussing guidelines for therapy, sur-
veillance, phenotype or genetics were included. Reviews
were mostly used to search the bibliography to identity
additional papers of interest. When newer papers were
based on or discussing older papers e.g. surveillance strat-
egy the newest paper was included. Each paper, which was
identified in the search, was reviewed in order to determine
suitability. Only English language articles up to January
2014 were included.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Histopathology of a juvenile polyp with characteristic cystic glands.
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Hamartomatous polyps in the GI-tract are rare com-
pared to neoplastic and hyperplastic polyps. However,
the hamartomatous polyp is the most common type of
polyps in children [1]. The prevalence in the entire popu-
lation is unknown but some suggest a prevalence of ap-
proximately 2% in the paediatric population [2].
Hamartomatous polyps are most often diagnosed by
endoscopy and symptoms include rectal bleeding, pain,
anaemia, prolapsing polyp, diarrhoea and/or melena [3].
The hamartomatous polyps vary in size and may have a
characteristic histological structure, which makes it pos-
sible to distinguish between the Peutz-Jeghers polyp andFigure 2 Histopathology of a juvenile polyp with dysplasia.the juvenile polyp. Peutz-Jeghers polyps are typically mul-
tilobulated with a papillary surface and branching bands
of smooth muscle covered by hyperplastic glandular
mucosa [4]. The term “juvenile polyps” refer to a special
histopathology and not the age of onset as the polyp might
be diagnosed at all ages. The juvenile polyp has a spherical
appearance and is microscopically characterized by over-
growth of an oedematous lamina propria with inflamma-
tory cells and cystic glands (Figures 1 and 2). It might be
difficult the distinguish between an inflammatory and a ju-
venile polyp [2].
Solitary hamartomatous polyps in the gastrointestinal
tract is generally not considered to be associated with an
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history of colorectal cancer or polyps should lead to suspi-
cion of HPS. In addition to the occurrence of polyps,
many of syndromes also manifest with extra-intestinal
findings such as developmental delay, dermatological ab-
normalities or extra-intestinal cancer. HPS should be dis-
tinguished from Adenomatous Polyposis Syndromes such
as Familiar Adenomatous Polyposis Syndrome (FAP) or
MUTYH-associated Polyposis (MAP), which are domi-
nated by the presence of adenomas.
The syndromes are inherited in an autosomal domin-
ant pattern with offspring having a 50% risk of inheriting
the condition. The expressivity of the phenotype is vari-
able and penetrance is often 100%. During the past two
decades several genes have been associated with HPS
(Table 1). Detection of a germline mutation in the pro-
band makes identification and surveillance of at-risk fam-
ily members possible. Thus genetic counselling should be
a cornerstone in the diagnostic approach to patients
suspected for a polyposis syndrome. Furthermore affected
patients and at-risk family members should be offered sur-
veillance. The lack of long-term follow-up studies of the
effect of surveillance, presumable ascertainment bias in
the reported risks of cancer and the somewhat unknown
pathogenic basis for cancer-development makes decision
on a surveillance program challenging.
HPS include several syndromes of which the following
are discussed in this article: Juvenile polyposis syndrome,
PTEN-hamartoma tumor syndrome, Peutz-Jeghers syn-
drome, and Hereditary mixed polyposis syndrome.
Juvenile polyposis syndrome
Juvenile polyposis syndrome (JPS) is characterized by the
occurrence of multiple juvenile polyps in the GI-tract. The
incidence is approximately between 1:100.000 to1:160 000
[3]. The number of polyps varies from 1 to over a 100,
and may be found in the entire GI-tract but mostly in the
colon, rectum and ventricle. The age at diagnosis varies
considerably, but symptoms usually present themselves in
the first and second decade [9].Table 1 Overview of the most common Hamartomatous Polyp
Genes Hallmark features
Juvenile polyposis syndrome SMAD4, BMPR1A Multiple GI-polyps, epistaxi
PTEN-hamartoma syndrome:
Cowden Syndrome





macules of the glans penis




(BMPR1A, GREM1) Atypical polyposis with juv
adenomas, hyperplastic and
*In SMAD4 mutation carriers.The diagnostic criteria for JPS was established in 1975
and later revised by Jass et al. [10]. According to these
one of the following must be present:
1) More than five juvenile polyps in the colorectum or/
and
2) Multiple juvenile polyps throughout the GI-tract or/
and
3) Any number of juvenile polyps with a family history
of juvenile polyposis
JPS is inherited in an autosomal dominant manner and
20-50% of affected patients have a positive family history
[9]. In patients fulfilling the diagnostic criteria it is possible
to detect mutations in BMPR1A in 20-30% of patients, and
in SMAD4 in 20-30% of the patients. Both genes are part
of the transforming growth factor (TGF-beta) pathway.
An increased lifetime risk for both colorectal cancer
(CRC) and gastric cancer has been documented in sev-
eral studies: Howe et al. reported a 38% lifetime risk of
developing CRC and 21% for upper GI cancer [11].
Brosens et al. reported a relative risk of developing CRC
of 34.0 with the cumulative lifetime risk of 38.7% [12].
Median age at diagnosis was in the latter study 42 years.
Pancreatic cancer, and cancer of the small intestine has
been reported in a small number of patients with JPS
[11,13]. Reports suggest that SMAD4-mutations carriers
have a significant higher frequency of gastric polyps and
gastric cancer than BMPR1A-mutation carriers [14,15].
There is no international consensus on treatment or
prophylactic surgery for patients. For some patients endo-
scopic polypectomies will be sufficient. Prophylactic total –
or subtotal colectomy or gastrectomy should be considered
in patients with multiple polyps, severe symptoms or a
family history of CRC [16-18]. Proctocolectomy and
subtotal colectomy with ileorectal anastomosis need
endoscopic follow-up because of high recurrence-rate
of polyps [16].
For asymptomatic at-risk members of JPS-families (e.g.
mutation-positive individuals) British recommendationsosis Syndromes
Cancer by site Approx. mutation
detection rate (%)
s,* telangiectasia* Colon, rectum and stomach 60% [2]
richilemmoma,
haly,
Breast, thyroid, uterus, colon Up to 80% [6]
pigmented As above 60% [7]





Colon and rectum Unknown
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1–2 years from age 15–18 years until age 70 and gastro-
duodenoscopy from age 25 with a 1–2 year interval [18].
Howe et al. suggested that mutation carriers and asymp-
tomatic patients should have colonoscopy every three
years from age 15 years, while patients who have polyps
should be examined every year [17]. They also sugges-
ted gastroduodenoscopy to be performed from age 15.
Latchford et al. concluded that that small-bowel disease is
not a significant clinical problem in JPS and as such sur-
veillance of the small intestines should not be performed
in all patients [3].
Patients with SMAD4 mutations should be screened
for hereditary hemorrhagic telangiectasia, (HHT) symp-
toms, in particular the presence of pulmonary AV-
malformations. McDonald et al. published guidelines
for managing HHT patients [19]. A recent report de-
scribed the presence of thoracic aortic dilatation in a
SMAD4-mutation carrier and the authors suggested
that the thoracic aorta should be screened in these pa-
tients [20].
BMPR1A is located in the same chromosomal region
as PTEN and larger deletions involving both genes have
been reported [21]. These patients present with a severe
form of JPS with onset in early childhood (sometimes
called Juvenile polyposis of infancy) or might have symp-
toms of both Cowden syndrome and JPS.
PTEN-hamartoma Tumour syndrome
PTEN-hamartoma Tumour syndrome include the clin-
ical entities of Cowden syndrome (CS), Bannayan-Riley-
Ruvalcaba (BRRS), PTEN-related Proteus syndrome (PS),
and Proteus-like syndrome.
Cowden syndrome
CS is characterized by overgrowth of multiple hamarto-
mas involving several organs. The incidence is thought
to be approximately 1:200 000, but the expressivity of
the syndrome varies greatly [6]. Because Cowden syn-
drome (CS) is likely underdiagnosed, the actual proportion
of de novo cases cannot be determined. CS is inherited in
an autosomal dominant manner and mutations may be
found in PTEN. The mutations are typically pointmuta-
tions or smaller deletions or insertions. The mutation-
detection rate in patients fulfilling the diagnostic criteria
has been reported to 80% [6] in earlier reports, however
the mutation-detection rate might be lower as suggested
by Pilarksi et al. [22].
The clinical features of CS involve benign mucocutane-
ous lesions and Lhermitte-Duclos Disease (LDD). LDD is
dysplatic cerebellar gangliocytoma and mucocutaneous le-
sions include trichilemmomas, acral keratoses and papillo-
matous lesions. Macrocephaly is a hallmark feature and
has been reported in 84% of CS patients with PTEN-mutations [23]. In the third decade of life more than 90%
of CS-patients have symptoms. International diagnostic
clinical criteria were established in 2000 [24] and have
been revised over the years. In a recent article Pilarski
et al. found that e.g. benign breast disease or genitouri-
nary malformations could not be used as diagnostic
criteria, whereas e.g. autism spectrum disorders, colon
cancer and esophageal glycogenic acanthosis could be in-
cluded [22]. The clinical criteria of the PTEN-hamartoma
tumor syndrome as suggested by Pilarski et al. can be
seen in Table 2.
The increased risk of cancer in CS-patients is well de-
scribed and involves especially the thyroid (non-medul-
lary) and breast. Bubien et al. [25] calculated standardised
incidence ratios (SIR) for several cancer-sites in a cohort
of PTEN-mutation positive patients. The authors found
SIR for breast cancer to be 39.1, thyroid cancer 43.2 (fe-
male) and 199.5 (male), melanoma 28.3 (female) and 39.4
(male) and endometrial cancer 48.7. The cumulative risk
of cancer was at the age of 70 years estimated to 85% for
any cancer, 77% for breast-cancer in females and 38% for
thyroid cancer (20). Tan et al. [26] reported a life-time risk
of breast cancer to be 85.2%, thyroid cancer 35.2%, endo-
metrial cancer 28.2%, colorectal cancer 9.0%, renal carcin-
oma 33.6% and melanoma 6%. The study included 368
PTEN-mutations positive individuals (295 index patients
and 73 relatives identified following screening) and thus
the high risk-estimates might be an ascertainment bias.
Hamartomatous polyps are the most common abnor-
mal finding in the GI-tract in CS-patients [27] and have
been reported in 35-85% of patients [28]. Ganglioneuro-
matous polyps, colonic lipomas and other types of polyps
such as hyperplastic polyps, adenomas or inflammatory
polyps might also be present. Heald et al. found that
50.4% (n = 62) of 127 patients with PTEN-mutations had
GI-polyps and 24 patients had both upper and lower GI-
polyps [28]. Stanich et al. [29] reported that 9 out of 10
patients meeting the diagnostic criteria had GI-polyps,
with 7 patients having more than one polyp.
Surveillance of the breast, thyroid and endometrial can-
cer is indicated and the increased risk of colorectal cancer,
renal cell carcinoma and possibly melanoma should be
taken into consideration. Tan et al. suggests that PTEN-
mutation carriers under the age of 18 years should undergo
annual targeted history and physical examination (includ-
ing dermatologic examination, neurological and psycho-
logical testing) as well as baseline thyroid examination with
ultrasound [26]. From age 30 women should have an an-
nual mammogram and an annual endometrial sampling or
transvaginal ultrasound. From age 40 both men and
woman should have biannual colonoscopy and biannual
renal ultrasound. For patients with a heavy polyp burden
more frequent colonoscopy should be considered [26].
Guidelines from the National Comprehensive Cancer
Table 3 Management program for men and woman with
CS from the National Comprehensive Cancer Network [30]
Woman
• Breast awareness starting at age 18 y
• Clinical breast exam, every 6–12 month, starting at age 25 y or
5–10 y before the earliest known breast cancer in the family
• Annual mammography and breast MRI screening starting at age
30–35 y or individualized based on earliest age of onset in family
• For endometrial cancer screening, encourage patient education and
prompt response to symptoms and participation in a clinical trial to
determine the effectiveness or necessity of screening modalities
• Discuss risk-reducing mastectomy and hysterectomy and counsel
regarding degree of protection, extent of cancer risk and
reconstruction options
• Address psychosocial, social, and quality-of-life aspects of undergoing
risk-reducing mastectomy and/or hysterectomy
Men and Woman
• Annual comprehensive physical exam starting at age 18 y or 5 y
before the youngest age of diagnosis of a component cancer in
the family (whichever comes first), with particular attention to
breast and thyroid exam
• Annual thyroid starting at age 18 y or 5-10 y before the earliest
known thyroid cancer in the family, whichever is earlier
• Colonoscopy, starting at age 35 y, then every 5 y or more frequently
if patient is symptomatic or polyps found
• Consider renal ultrasound starting at age 40 y, then every 1-2 y
• Dermatological management may be indicated for some patients
• Consider psychomotor assessment in children at diagnosis and
brain MRI if there are symptoms
• Education regarding the signs and symptoms of cancer
Adapted with permission from the NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines(r)) for Genetic/Familial High-Risk Assessment:
Breast and Ovarian V.1.2014. (c) 2014 National Comprehensive Cancer Network,
Inc. All rights reserved. The NCCN Guidelines(r) and illustrations herein may
not be reproduced in any form for any purpose without the express written
permission of the NCCN. To view the most recent and complete version of the
NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER
NETWORK(r), NCCN(r), NCCN GUIDELINES(r), and all other NCCN Content are
trademarks owned by the National Comprehensive Cancer Network, Inc.
Table 2 Clinical criteria for PTEN hamartoma tumor
syndrome as suggested by Pilarski et al. [22]
Major criteria
• Breast cancer
• Endometrial cancer (epithelial)
• Thyroid cancer (follicular)
• Gastrointestinal hamartomas (including ganglioneuromas, but
excluding hyperplastic polyps; ≥3)
• Lhermitte-Duclos disease (adult)
• Macrocephaly (≥97 percentile: 58 cm for females, 60 cm for males)
• Macular pigmentation of the glans penis
• Multiple mucocutaneous lesions (any of the following)
o Multiple trichilemmomas (≥3, at least one biopsy proven)
o Acral keratoses (≥3 palmoplantar keratotic pits and/or acral
hyperkeratotic papules)
o Mucocutaneous neuromas (≥3)
o Oral papillomas (particularly on tongue and gingiva),
multiple (≥3) OR biopsy proven OR dermatologist diagnosed
Minor criteria
• Autism spectrum disorder
• Colon cancer
• Esophageal glycogenic acanthosis (≥3)
• Lipomas (≥3)
• Mental retardation (ie, IQ ≤ 75)
• Renal cell carcinoma
• Testicular lipomatosis
• Thyroid cancer (papillary or follicular variant of papillary)
• Thyroid structural lesions (eg, adenoma, multinodular goiter)
• Vascular anomalies (including multiple intracranial developmental
venous anomalies)
Operational diagnosis in an individual (either of the following)
1. Three or more major criteria, but one must include macrocephaly,
Lhermitte-Duclos disease, or gastrointestinal hamartomas; or
2. Two major and three minor criteria.
Operational diagnosis in a family where one individual meets
revised PTEN hamartoma tumor syndrome clinical diagnostic
criteria or has a PTEN mutation:
1. Any two major criteria with or without minor criteria; or
2. One major and two minor criteria; or
3. Three minor criteria.
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sizes addressing the risk for relatives, genetic counseling
and discussion of reproductive options [30].Bannayan-Riley-Ruvalcaba
Bannayan-Riley-Ruvalcaba syndrome is a part of the
clinical spectrum caused by PTEN-mutations. Marsch
et al. found that 60% of 43 patients with clinical BRRS
had germline mutations in PTEN [7].BRRS is characterized by macrocephaly (as in CS), lipo-
matosis and pigmented macules of the glans penis. Other
features are high birth weight, hamartomatous intestinal
polyposis and intellectual disability [23]. Multiple juvenile
polyps have been reported in about 25% of cases [31].
Screening recommendations have not been established for
BRRS but BRRS patients with PTEN-mutations should
undergo the same surveillance programs as patients
with CS.
PTEN-related Proteus syndrome and Proteus-like-syndrome
PTEN-related Proteus syndrome (PS) and Proteus-like
syndrome are traditionally placed under the PTEN-hamar-
toma syndrome. The syndromes are characterized by
disproportionate overgrowth of affected tissues and may
affect the skeleton, skin and central nervous system. The
clinical presentations of the syndromes vary greatly.
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activation mutation in AKT1 [32]. Although cases of pa-
tients with PS or Proteus-like-syndrome with PTEN-
germline mutation have been described [33,34] some
has questioned the clinical diagnosis of these patients
[35,36]. Nevertheless, both ATK1 and PTEN work in the
PI3KCA/AKT - pathway. Treatment and surveillance of
PS is based on experience from reported cases and is
symptomatic, but the complications and symptoms of
PS are often severe. Turner et al. [36] suggested periodic
ophthalmologic evaluations and that baseline-brain MRI
(because of CNS-complications) and educational inter-
vention (because of cognitive impairment) could be con-
sidered. The association between deep vein thrombosis
and PS has been reported several times and Turner et al.
[36] concluded that pulmonary embolism is a major
contributor to early mortality in PS. However, there is
still no evidence or data to support recommendation of
anticoagulation therapy.
Peutz-Jeghers syndrome
Peutz-Jeghers syndrome (PJS) is characterized by muco-
cutanous melanosis, polyposis of the GI-tract, luminal
gastrointestinal cancer and extraintestinal cancer. The in-
cidence has been estimated to be approximately 1:8300
and 1:200.000 [37]. About 55% of patients have an affected
parent.
Patients often present themselves in infancy or early
childhood with rectal bleeding, intestinal invagination,
anemia and mucocutaneous pigmentations. The latter
are present in approximately 95% of patients and occur
on the lips, buccal mucosa and the perianal area. The le-
sions might fade after puberty but may persist on theFigure 3 Peutz-Jeghers polyp found at endoscopy.buccal mucosa [8]. The number of polyps might vary from
one to hundreds and are located throughout the GI-tract
although mostly in the small intestines and colon [8]
(Figure 3). The polyps reveal a characteristic histopath-
ology as described earlier: The polyps have convoluted,
elongated glands and an arborizing pattern of growth
and consist of a branching framework of smooth muscle
and connective tissue lined by normal epithelium [38].
The polyps may also be found extra-intestinally e.g. in
the gall bladder, the bronchi, the urinary bladder and
the ureter [39].
PJS is inherited in an autosomal dominant manner.
Germline mutations can be found in STK11 and include
point-mutations as well as larger deletions. STK11 is a
tumour suppressor gene affecting the mTOR pathway.
Mutations can be found in up to 94% of patients who
fulfil the diagnostic criteria [40].
Diagnosis is based on the clinical presentation, the
characteristic histopathology of the polyps, the results
of genetic testing and family history. The diagnosis
can be made when one of the following criteria is
present:
1. Two or more histologically confirmed Peutz-Jeghers
polyps
2. Any number of PJ-polyps detected in one individual
who has a family history of PJS within close
relative(s).
3. Characteristic mucocutaneous pigmentation in an
individual who has a family history of PJS within
close relative(s).
4. Any number of PJ-polyps in an individual who also
has characteristic mucocutaneous pigmentations.
Table 4 Relative risk of cancer in Peutz-Jeghers syndrome
Resta et al. [41] Giardiello et al. [42]
Study design Retrospective cohort
study
Meta-analysis
Any cancer 15.1 (CI 10.5-21.2) 15.2
Breast 12.5 (CI 5.1-26.0) 15.2
Cervix 55.6 (CI 17.7-134.0) 1.5
Gynaecological cancers 27.7 (CI 11.3-57.6) NA
Colorectal cancer 13.5 (CI 4.3-32-5) 84.0 (Colon)
Pancreas 139.7 (CI 61.1-276.4) 132





Small intestines NA 520.0
Stomach NA 213.0
Oesophagus NA 57.0
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extra-intestinal cancer in patients with PJS is well docu-
mented and high (Table 4). Resta et al. investigated the
prevalence and risk of cancer in a retrospective cohort
study of 119 patients who either fulfilled the diagnostic
criteria or had a mutation in STK11 [41]. The most fre-
quent sites of malignancy were the GI-tract and the
breast. Giardiello et al. conducted a meta-analysis of 210
individuals described in six publications. A statistically
high significant RR for both GI-cancer and extra intes-
tinal cancer was observed, but no significant RR for tes-
ticular or cervical cancer [42] (Table 4); the overall
cumulative risk for cancer was over 90% in patients with
PJS. Van Lier et al. concluded that PJS patients already
at a young age carry a high cancer risk and the authors
found the average age at cancer-diagnosis (not site-
specific) to be 42 years [43]. The cumulative risk of can-
cer increases with age in several studies [41,44].
Surveillance is essential because of the risk of compli-
cations to polyps such as intussusception as well as theTable 5 List of other syndromes where hamartomatous polyp
Clinical hallmarks
Gorlin syndrome Keratocysts of the jaw, hyperkeratosis of palm an
skeleton abnormalities, macrocephaly, frontal bo
Multiple endocrine
neoplasia type 2B
Mucosal neuromas of the lips an tongue, medull
facies with enlarged lips and tongue, an asthenic
thyroid cancer.
Neurofibromatosis type 1 Café au lait spots, axillary and inguinal freckling,
Birt-Hogg-Dubé Skin fibrofolliculomas, spontaneous pneumothorincreased risk of cancer. Especially surveillance of the
breast, colon and rectum and the small intestines should
be established. Different guidelines and recommenda-
tions have been suggested through the past decade
[8,37,38,45], however, Beggs et al. [8] compared the sur-
veillance programs described in the literature. The au-
thors advocate to postpone the endoscopic screening of
the GI-tract until late childhood/early adolescence and
suggest that a baseline colonoscopy and upper gastros-
copy is performed at age 8 years, or earlier if the patient
is symptomatic, and repeated every third year if polyps
are detected [8]. Otherwise the screening program should
begin at age 18 and then performed every 3 years. At the
age of 50 years the frequency of screening is suggested to
increase to every 1–2 years because of the age-depending
cancer risk. Beggs et al. suggested that small bowel screen-
ing should be initiated at age 8 and performed every
3 years if polyps were found or else from age 18. Korsse
et al. discussed radiologic and endoscopic imaging modal-
ities of the small bowel and suggested small bowel surveil-
lance in PJS patients every 2–3 years from age 8–10 (40).
Korsse et al. also stated that the removal of small bowel
hamartomas reduces the need for elective and emergency
laparotomy and that when significant polyps are detected
(10–15 mm) push enteroscopy should be the preferred
and polyps removed [46].
Routine-screening of pancreas has recently been inves-
tigated and the authors found that surveillance should
only be performed in defined research protocols as sur-
veillance has not yet proven to reduce mortality [47].
As part of the Dutch recommendations for surveillance
Van lier et al. suggested that patients with a positive fam-
ily history were screened with physical examination in-
cluding testicular palpation and haemoglobin analysis
from the age of 10 years [43]. Breast examination and
breast MRI should start from 25 years of age. Colonos-
copy should start at age 25–30 years with an interval of
2–5 years depending on findings (38).
Hereditary mixed polyposis syndrome
Hereditary mixed polyposis syndrome (HMPS) was de-
scribed by Whitelaw et al. in a large family with atypicals are frequent
Gene Cancer
d soles, basal cell carcinomas,
ssing
PTCH1 Basal cell carcinomas,
medullablastoma
ated corneal nerve fibers, distinctive
“marfarnoid habitus, and medullary
RET Medullary thyroid cancer,
pheochromocytoma
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[48]. The condition is characterized by an atypical pattern
of polyposis in the colon and rectum. Affected individuals
may develop juvenile polyps, hyperplastic polyps or aden-
omas. Colorectal carcinoma occurs in a high proportion
of reported families [49]. The genetic cause (s) of HMPS
remains elusive. HMPS has been mapped to the chromo-
somal region of 10q23, which includes BMPR1A [50] and
O’Riordan et al. found a BMPR1A mutation in one family
[51]. Jaeger et al. reported that a duplication in the 3’ end
of the SCG5 gene and a region upstream of GREM1-locus
can cause HMPS [49].
Consensus surveillance programs have not been pub-
lished and the existing literature is not sufficient to rec-
ommend or suggest frequency of surveillance. However,
as BMPR1A mutation-carriers have a high risk of cancer
in JPS, it seems reasonable to offer mutations-carriers a
surveillance program with colonoscopy [51].
Other syndromes with the presence of hamartomatous
polyps
The presence of hamartomatous polyps is described in
patients with other syndromes such as Neurofibromatosis
type 1, Multiple Endocrine Neoplasia type 2B, Gorlin Syn-
drome and Birt-Hogg-Dubé. The syndromes are listed in
Table 5.
Cronkhite-Canada Syndrome is also characterized by
gastrointestinal hamartomatous polyposis and is some-
times classified as a HPS. The syndrome is not consid-
ered to be hereditary but appears to be an autoimmune
inflammatory condition [52].
Genetic testing
The sometimes-difficult clinical and histopathological
distinction between different HPS makes genetic testing
important in the diagnostic approach to these patients.
The development of Next Generation Sequencing (NGS)
makes it possible to sequence DNA in a faster and less
expensive way compared to traditional Sanger-sequencing.
NGS holds a lot of possibilities for patients suspected of a
polyposis syndrome, as it is now possible the test a panel
of genes – or even all genes (exome-sequencing) -making
an early and precise diagnosis. Nevertheless, it is not al-
ways possible – despite a clear histological and endoscopic
diagnosis as well as a positive family history- to detect a
germline mutation in any of the known genes. This indi-
cates that new candidate genes are still to be discovered
and that the genetic technology could be improved.
Conclusion
Hamartomatous Polyposis Syndromes (HPS) are rare
genetic syndromes characterized by the development of
hamartomatous polyps in the gastrointestinal tract and
an increased risk of cancer. Early diagnosis is importantas affected patients and at-risk family members should
be offered surveillance from an early age. The rapid de-
velopment in genetics makes it possible to use genetic
testing more often and thus genetic counselling should be
a cornerstone in families with Hamartomatous Polyposis
Syndromes.
Abbreviations
GI-tract: Gastrointestinal tract; HPS: Hamartomatous Polyposis Syndromes; NGS: Next
Generation Sequencing; JPS: Juvenile polyposis syndrome; PJS: Peutz-Jeghers
syndrome; CS: Cowden Syndrome; BRRS: Bannayan-Riley-Ruvalcaba Syndrome;
PS: Proteus syndrome; MEN2B: Multiple Endocrine Neoplasia type 2B;
SIR: Standardised incidence ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JAM: The main author who has conducted the main part of the literature
search and written the first draft. QN: Contributed especially to the sections
concerning surveillance and surgical interventions. BK: Contributed mainly to
the sections concerning genetics and Next Generation Sequencing. NCB:
Contributed especially to the section of Peutz-Jeghers Syndrome as well as
providing pictures for the review. HTP: Contributed with histopathological
descriptions and illustrations. OLB: Contributed especially to the part of
Juvenile Polyposis syndrome, genetics and surveillance. All authors read and
approved the final manuscript.
Author details
1Department of Clinical Genetics, Odense University Hospital and Institute of
Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000
Odense C, Denmark. 2Surgical Department A, Odense University Hospital
Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark. 3Department of
Clinical Genetics, Odense University Hospital Denmark, Sdr. Boulevard 29,
5000 Odense C, Denmark. 4Department of Surgery, Hvidovre Hospital,
Kettegaard Alle 30, 2650 Hvidovre, Denmark. 5Department of Pathology,
Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Received: 8 April 2014 Accepted: 19 June 2014
Published: 15 July 2014
References
1. Hoffenberg EJ, Sauaia A, Maltzman T, Knoll K, Ahnen DJ: Symptomatic
colonic polyps in childhood: not so benign. J Pediatr Gastroenterol Nutr
1999, 28:175–181.
2. Brosens LA, Langeveld D, van Hattem WA, Giardiello FM, Offerhaus GJ:
Juvenile polyposis syndrome. World J Gastroenterol 2011, 17:4839–4844.
3. Latchford AR, Neale K, Phillips RK, Clark SK: Juvenile polyposis syndrome: a
study of genotype, phenotype, and long-term outcome. Dis Colon
Rectum 2012, 55:1038–1043.
4. Jass JR: Colorectal polyposes: from phenotype to diagnosis. Pathol Res
Pract 2008, 204:431–447.
5. Nugent KP, Talbot IC, Hodgson SV, Phillips RK: Solitary juvenile polyps: not
a marker for subsequent malignancy. Gastroenterology 1993, 105:698–700.
6. Uppal S, Mistry D, Coatesworth AP: Cowden disease: a review. Int J Clin
Pract 2007, 61:645–652.
7. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D,
Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM,
Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM,
Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, LePrat F,
Odent S, Toulouse C, Olopade OI, Sobol H, Tishler S, et al: Mutation
spectrum and genotype-phenotype analyses in Cowden disease and
Bannayan-Zonana syndrome, two hamartoma syndromes with germline
PTEN mutation. Hum Mol Genet 1998, 7:507–515.
8. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L,
Blanco I, Bulow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ,
Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Philips RK, Hyer W,
de Leon Ponz M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S,
Thomas HJ, Wijnen JT, Clark SK, Hodgson SV, et al: Peutz-Jeghers
Jelsig et al. Orphanet Journal of Rare Diseases 2014, 9:101 Page 9 of 10
http://www.ojrd.com/content/9/1/101syndrome: a systematic review and recommendations for management.
Gut 2010, 59:975–986.
9. Manfredi M: Hereditary hamartomatous polyposis syndromes:
understanding the disease risks as children reach adulthood.
Gastroenterol Hepatol (N Y) 2010, 6:185–196.
10. Jass JR, Williams CB, Bussey HJ, Morson BC: Juvenile polyposis–a
precancerous condition. Histopathology 1988, 13:619–630.
11. Howe JR, Mitros FA, Summers RW: The risk of gastrointestinal carcinoma
in familial juvenile polyposis. Ann Surg Oncol 1998, 5:751–756.
12. Brosens LA, van Hattem A, Hylind LM, Iacobuzio-Donahue C, Romans KE,
Axilbund J, Cruz-Correa M, Tersmette AC, Offerhaus GJ, Giardiello FM: Risk
of colorectal cancer in juvenile polyposis. Gut 2007, 56:965–967.
13. Walpole IR, Cullity G: Juvenile polyposis: a case with early presentation
and death attributable to adenocarcinoma of the pancreas. Am J Med
Genet 1989, 32:1–8.
14. Aretz S, Stienen D, Uhlhaas S, Stolte M, Entius MM, Loff S, Back W, Kaufmann A,
Keller KM, Blaas SH, Siebert R, Vogt S, Spranger S, Holinski-Feder E, Sunde L,
Propping P, Friedl W: High proportion of large genomic deletions and a
genotype phenotype update in 80 unrelated families with juvenile
polyposis syndrome. J Med Genet 2007, 44:702–709.
15. Friedl W, Uhlhaas S, Schulmann K, Stolte M, Loff S, Back W, Mangold E,
Stern M, Knaebel HP, Sutter C, Weber RG, Pistorius S, Burger B, Propping P:
Juvenile polyposis: massive gastric polyposis is more common in
MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet
2002, 111:108–111.
16. Oncel M, Church JM, Remzi FH, Fazio VW: Colonic surgery in patients with
juvenile polyposis syndrome: a case series. Dis Colon Rectum 2005,
48:49–55. discussion 55–46.
17. Howe JR, Ringold JC, Hughes JH, Summers RW: Direct genetic testing for
Smad4 mutations in patients at risk for juvenile polyposis. Surgery 1999,
126:162–170.
18. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD,
Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P,
Fairclough PD, Woodhouse CR: Guidelines for colorectal cancer screening
and surveillance in moderate and high risk groups (update from 2002).
Gut 2010, 59:666–689.
19. McDonald J, Bayrak-Toydemir P, Pyeritz RE: Hereditary hemorrhagic
telangiectasia: an overview of diagnosis, management, and
pathogenesis. Genet Med 2011, 13:607–616.
20. Teekakirikul P, Milewicz DM, Miller DT, Lacro RV, Regalado ES, Rosales AM,
Ryan DP, Toler TL, Lin AE: Thoracic aortic disease in two patients with
juvenile polyposis syndrome and SMAD4 mutations. Am J Med Genet A
2013, 161A:185–191.
21. Dahdaleh FS, Carr JC, Calva D, Howe JR: Juvenile polyposis and other
intestinal polyposis syndromes with microdeletions of chromosome
10q22-23. Clin Genet 2012, 81:110–116.
22. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E: Cowden
Syndrome and the PTEN Hamartoma Tumor Syndrome: Systematic Review
and Revised Diagnostic Criteria. J Natl Cancer Inst 2013, 105:1607–1616.
23. Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW: Predicting PTEN
mutations: an evaluation of Cowden syndrome and Bannayan-Riley-
Ruvalcaba syndrome clinical features. J Med Genet 2011, 48:505–512.
24. Eng C: Will the real Cowden syndrome please stand up: revised
diagnostic criteria. J Med Genet 2000, 37:828–830.
25. Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P,
Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C,
Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F: High cumulative risks
of cancer in patients with PTEN hamartoma tumour syndrome. J Med
Genet 2013, 50:255–263.
26. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C: Lifetime cancer
risks in individuals with germline PTEN mutations. Clin Cancer Res 2012,
18:400–407.
27. Coriat R, Mozer M, Caux F, Chryssostalis A, Terris B, Grandjouan S,
Benamouzig R, Martin A, Chaussade S: Endoscopic findings in Cowden
syndrome. Endoscopy 2011, 43:723–726.
28. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C: Frequent
gastrointestinal polyps and colorectal adenocarcinomas in a prospective
series of PTEN mutation carriers. Gastroenterology 2010, 139:1927–1933.
29. Stanich PP, Owens VL, Sweetser S, Khambatta S, Smyrk TC, Richardson RL,
Goetz MP, Patnaik MM: Colonic polyposis and neoplasia in Cowden
syndrome. Mayo Clin Proc 2011, 86:489–492.30. Referenced with permission from the NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines(r)) for Genetic/Familial High-Risk Assessment:
Breast and Ovarian V.1.2014. (c) National Comprehensive Cancer Network,
Inc 2014. All rights reserved. Accessed [June 28, 2014]. To view the most
recent and complete version of the guideline, go online to www.nccn.org.
NATIONAL COMPREHENSIVE CANCER NETWORK(r), NCCN(r), NCCN
GUIDELINES(r), and all other NCCN Content are trademarks owned by the
National Comprehensive Cancer Network, Inc.
31. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA: Bannayan-Riley-Ruvalcaba
syndrome. Am J Med Genet 1992, 44:307–314.
32. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J,
Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P,
Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM,
Keppler-Noreuil KM, Kuznetsov SA, Miaymoto RT, Newman K, Ng D, O’Brien
K, Rothenberg S, Schwartzentruber DJ, Singhai V, Tirabosco R, Upton J, et al:
A mosaic activating mutation in AKT1 associated with the Proteus
syndrome. N Engl J Med 2011, 365:611–619.
33. Smith JM, Kirk EP, Theodosopoulos G, Marshall GM, Walker J, Rogers M, Field
M, Brereton JJ, Marsh DJ: Germline mutation of the tumour suppressor
PTEN in Proteus syndrome. J Med Genet 2002, 39:937–940.
34. Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, Winter RM,
Eng C: Association of germline mutation in the PTEN tumour suppressor
gene and Proteus and Proteus-like syndromes. Lancet 2001, 358:210–211.
35. Cohen MM Jr, Turner JT, Biesecker LG: Proteus syndrome: misdiagnosis
with PTEN mutations. Am J Med Genet A 2003, 122A:323–324.
36. Turner JT, Cohen MM Jr, Biesecker LG: Reassessment of the Proteus
syndrome literature: application of diagnostic criteria to published cases.
Am J Med Genet A 2004, 130A:111–122.
37. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW,
van Leerdam ME: High cancer risk in Peutz-Jeghers syndrome: a
systematic review and surveillance recommendations. Am J Gastroenterol
2010, 105:1258–1264. author reply 1265.
38. Giardiello FM, Trimbath JD: Peutz-Jeghers syndrome and management
recommendations. Clin Gastroenterol Hepatol 2006, 4:408–415.
39. Vogel T, Schumacher V, Saleh A, Trojan J, Moslein G: Extraintestinal polyps
in Peutz-Jeghers syndrome: presentation of four cases and review of the
literature. Deutsche Peutz-Jeghers-Studiengruppe. Int J Colorectal Dis
2000, 15:118–123.
40. Aretz S, Stienen D, Uhlhaas S, Loff S, Back W, Pagenstecher C, McLeod DR,
Graham GE, Mangold E, Santer R, Propping P, Friedl W: High proportion of
large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat
2005, 26:513–519.
41. Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R,
Lastella P, Susca FC, Bozzao C, Loconte DC, Sabbà C, Urso E, Sala P,
Fornasarig M, Grammatico P, Piepoli A, Host C, Turchetti D, Viel A, Memo L,
Giunti L, Stigliano V, Varesco L, Bertario L, Genuardi M, Lucci Cordisco E,
Tibletti MG, Di Gregorio C, Andriulli A, de Leon Ponz M, et al: Cancer risk
associated with STK11/LKB1 germline mutations in Peutz-Jeghers
syndrome patients: results of an Italian multicenter study. Dig Liver Dis
2013, 45:606–611.
42. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM,
Booker SV, Cruz-Correa M, Offerhaus JA: Very high risk of cancer in familial
Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447–1453.
43. van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW,
Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME: High cancer
risk and increased mortality in patients with Peutz-Jeghers syndrome.
Gut 2011, 60:141–147.
44. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ,
Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM,
Gruber SB, Offerhaus GJ, de Rooij FW, Wilson JH, Hansmann A, Möslein G,
Royer-Pokora B, Vogel T, Phillips RK, Spigelman AD, Houlston RS: Frequency
and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res
2006, 12:3209–3215.
45. Barnard J: Screening and surveillance recommendations for pediatric
gastrointestinal polyposis syndromes. J Pediatr Gastroenterol Nutr 2009,
48(Suppl 2):S75–S78.
46. Korsse SE, Dewint P, Kuipers EJ, van Leerdam ME: Small bowel endoscopy
and Peutz-Jeghers syndrome. Best Pract Res Clin Gastroenterol 2012,
26:263–278.
47. Korsse SEHF, van Lier MG, Biermann K, Offerhaus GJ, Krak N, Looman CW,
van Veelen W, Kuipers EJ, Wagner A, Dekker E, Mathus-Vliegen EM,
Jelsig et al. Orphanet Journal of Rare Diseases 2014, 9:101 Page 10 of 10
http://www.ojrd.com/content/9/1/101Fockens P, van Leerdam ME, Bruno MJ: Pancreatic cancer risk in
Peutz-Jeghers syndrome patients: a large cohort study and implications
for surveillance. J Med Genet 2013, 50:59–64.
48. Whitelaw SC, Murday VA, Tomlinson IP, Thomas HJ, Cottrell S, Ginsberg A,
Bukofzer S, Hodgson SV, Skudowitz RB, Jass JR, Talbot IC, Northover JM,
Bodmer WF, Solomon E: Clinical and molecular features of the hereditary
mixed polyposis syndrome. Gastroenterology 1997, 112:327–334.
49. Jaeger E, Leedham S, Lewis A, Segditsas S, Becker M, Cuadrado PR, Davis H,
Kaur K, Heinimann K, Howarth K, East J, Taylor J, Thomas H, Tomlinson I:
Hereditary mixed polyposis syndrome is caused by a 40-kb upstream
duplication that leads to increased and ectopic expression of the BMP
antagonist GREM1. Nat Genet 2012, 44:699–703.
50. Cao X, Eu KW, Kumarasinghe MP, Li HH, Loi C, Cheah PY: Mapping of
hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by
genomewide high-density single nucleotide polymorphism (SNP) scan
and identification of BMPR1A loss of function. J Med Genet 2006, 43:e13.
51. O'Riordan JM, O'Donoghue D, Green A, Keegan D, Hawkes LA, Payne SJ,
Sheahan K, Winter DC: Hereditary mixed polyposis syndrome due to a
BMPR1A mutation. Colorectal Dis 2010, 12:570–573.
52. Sweetser S, Ahlquist DA, Osborn NK, Sanderson SO, Smyrk TC, Chari ST,
Boardman LA: Clinicopathologic features and treatment outcomes in
Cronkhite-Canada syndrome: support for autoimmunity. Dig Dis Sci 2012,
57:496–502.
doi:10.1186/1750-1172-9-101
Cite this article as: Jelsig et al.: Hamartomatous polyposis syndromes: A
review. Orphanet Journal of Rare Diseases 2014 9:101.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
